Market Overview

Synta Announces Encouraging Results of Ganetespib GALAXY-1 Trial at ECC 2013


Synta Pharmaceuticals (NASDAQ: SNTA) today announced presentation
of results from the GALAXY-1 trial, a global, randomized, multi-center
Phase 2b/3 study designed to identify the patients with advanced
non-small cell lung adenocarcinoma most likely to benefit from
second-line treatment with the Company's lead drug candidate, the Hsp90
inhibitor ganetespib. The results, from a planned interim analysis
conducted in May, will be presented at the 2013 ECCO/ESMO/ESTRO
conference and include a review of interim findings previously presented
at ASCO 2013 as well as additional results for two of the study's
prespecified primary patient populations.

“We are encouraged by the improvements in PFS and OS in patients treated
with ganetespib in the GALAXY-1 study,” said Dr. Vojo Vukovic,

See full press release

Posted-In: News Guidance Management Global


Related Articles (SNTA)

View Comments and Join the Discussion!